{"disease":{"id":"microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab.md","name":"microsatellite instability high msi h or mismatch repair deficient dmmr colorectal cancer in adults in combination with nivolumab and ipilimumab and fluorouracil leucovorin irinotecan and oxaliplatin mfolfox6 and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}